Fusion Health Care launches COVID-19 drug favipiravir and an immunity booster


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ Mr Madhu Ramadugu with the drug
Fusion Health Care Pvt Ltd, a leading innovative pharmaceutical company based at Hyderabad, has announced the launch of its Favipiravir drug under the brand name XARAVIR, for the treatment of mild to moderate COVID-19 cases.

Fusion Health Care Pvt Ltd, a leading innovative pharmaceutical company based at Hyderabad, has announced the launch of its favipiravir drug under the brand name XARAVIR, for the treatment of mild to moderate COVID-19 cases.

“It gives us immense satisfaction to launch ‘XARAVIR’ as this drug has the potential to save precious lives. We have launched the product at an affordable price and strive to make it available in sufficient quantities to meet high demand for the drug in the Indian market,” stated Mr Madhu Ramadugu, Managing Director.

“We have developed a good recognition in the Indian Pharmaceutical industry with frequent launch of innovative products. In June 2019, we have launched SCORBIX (Vitamin C 1.5 g injection) which is prominently used in the treatment of Sepsis backed up by clinical trials and global protocols. In the current pandemic situation, SCORBIX is used in the treatment of COVID patients due to its antiviral mechanisms and strong immunity build up. Presently, SCORBIX is widely used in all renowned Hospitals across India,” stated Mr. Krishnendu Paul, General Manager.

Fusion Health Care is known for its innovation - with many “First Time in India Products” which include – SCORBIX (Vitamin C 1.5 g Injection), DIFIDOX (Doxycycline Injection 100 mg) the No.1 brand in India predominantly used in treating Dengue, Malaria & Fever of unknown origin, STAPHONEX (Flucloxacillin Injection 1 g/500 mg), ISEP (Isepamicin Injection 200/400 mg) and many more.

The company has recently launched an Immunity Booster product under the brand name D’FEND. It consists of Vitamin C 1000 mg + Zinc 10 mg, available in sugar free orange flavour, in a tube of 20 effervescent tablets. The role & benefits of Vitamin C + Zinc have been published in many established journals that indicate to improve immunity and avoid Flu.

Marking its 13th anniversary, Fusion Health Care inaugurated its R&D Facility in Hyderabad to bring innovative & affordable products for Indian Market.

Fusion Health Care has a strong Pan-India presence with a field force of 600 employees and an innovative portfolio of Critical Care & Cardio-Diabetes products.

The company also has its own 24-Hour Help line “Fusion Cares” which will enhance the access to its products including XARAVIR (Favipiravir) during this tough times.

Tags : #FusionHealthCare #MrMadhuRamadugu #ImmunityBooster #Favipiravir

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026